Phase 3 trial in 12,717 household contacts of TB patients in India: VPM1002 and Immuvac did not show efficacy vs placebo against all confirmed TB (VPM1002 efficacy 21.4%, 95% CI -8.9% to 43.2%); both were well tolerated.
RCTn = 12,717
Singh et al. Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial)